1. KD. Tripathi. Estrogens, Progestins and Contraceptives. Essentials of medical pharmacology. Seventh edition. 2013. Page – 316-319.
2. Bernard P. Schimmer and Keith L. Parker. Contraception and Pharmacotherapy of Obstetrical and Gynecological disorders. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 1848.
3. Gerald G. Briggs and Roger K. Freeman. H. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 1899-1901.
4. Lumara Health, Inc. Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on August 2014] [Accessed 30th November 2020] https://clinicaltrials.gov/ct2/show/NCT01899846
5. Yesha Patel and Martha M. Rumore. Hydroxyprogesterone Caproate Injection (Makena) One Year Later to Compound or Not to Compound That Is the Question. NCBI; PMC US National Library of Medicine, National Institute of Health. July 2012. [Accessed 30th November 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411212/
6. Sun Pharmaceutical Ltd. U.S. Food & Drug Administration. [Revised on March 2019] [Accessed 30th November 2020] https://sunpharma.com/sites/default/files/hydroxyprogesterone-caproate-inj-pil-208381.pdf
7. AMAG Pharmaceuticals, Inc. U.S. Food & Drug Administration. [Revised on February 2018] [Accessed 30th November 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021945s012lbl.pdf